WFRF:(Virchow JC)
Sökning: WFRF:(Virchow JC) > Clinically relevant...
LIBRIS Formathandbok (Information om MARC21)
| Fältnamn | Indikatorer | Metadata |
|---|---|---|
| 000 | 03530naa a2200457 4500 | |
| 001 | oai:prod.swepub.kib.ki.se:127116960 | |
| 003 | SwePub | |
| 008 | 240701s2013 | |||||||||||000 ||eng| | |
| 024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1271169602 URI |
| 024 | 7 | a https://doi.org/10.1159/0003514042 DOI |
| 040 | a (SwePub)ki | |
| 041 | a engb eng | |
| 042 | 9 SwePub | |
| 072 | 7 | a ref2 swepub-contenttype |
| 072 | 7 | a art2 swepub-publicationtype |
| 100 | 1 | a Meltzer, E4 aut |
| 245 | 1 0 | a Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis |
| 264 | c 2013-05-04 | |
| 264 | 1 | b S. Karger AG,c 2013 |
| 520 | a <b><i>Background:</i></b> It is unclear what constitutes a clinically meaningful response for allergic rhinitis (AR) outcomes. The objectives of these post hoc analyses were (1) to define a clinically meaningful response using novel efficacy analyses (including a responder analysis), and (2) to compare the efficacy of MP29-02 [a novel intranasal formulation of azelastine hydrochloride (AZE) and fluticasone propionate (FP)] with commercially available FP, AZE and placebo in seasonal AR (SAR) patients, using these novel analyses. <b><i>Methods:</i></b> 610 moderate-to-severe SAR patients (≥12 years old) were randomized into a double-blind, placebo-controlled, 14-day, parallel-group trial. Change from baseline in the reflective total nasal symptom score (rTNSS) over 14 days was the primary outcome. Post hoc endpoints included the sum of nasal and ocular symptoms (rT7SS), efficacy by disease severity and by predominant nasal symptom, and a set of responder analyses. <b><i>Results:</i></b> MP29-02 most effectively reduced rT7SS (relative greater improvement: 52% to FP; 56% to AZE) and both nasal and ocular symptoms irrespective of severity. More MP29-02 patients achieved a ≥30, ≥50, ≥60, ≥75 and ≥90% rTNSS reduction, which occurred days faster than with either active comparator; MP29-02 alone was superior to placebo at the ≥60% (or higher) threshold. One in 2 MP29-02 patients achieved a ≥50% rTNSS reduction and 1 in 6 achieved complete/near-to-complete response. Only MP29-02 was consistently superior to placebo for all patients, whatever their predominant symptom. <b><i>Conclusions:</i></b> MP29-02 provided faster and more complete symptom control than first-line therapies. It was consistently superior irrespective of severity, response criteria or patient-type, and may be considered the drug of choice for moderate-to-severe AR. These measures define a new standard for assessing relevance in AR. | |
| 700 | 1 | a Ratner, P4 aut |
| 700 | 1 | a Bachert, Cu Karolinska Institutet4 aut |
| 700 | 1 | a Carr, W4 aut |
| 700 | 1 | a Berger, W4 aut |
| 700 | 1 | a Canonica, GW4 aut |
| 700 | 1 | a Hadley, J4 aut |
| 700 | 1 | a Lieberman, P4 aut |
| 700 | 1 | a Hampel, FC4 aut |
| 700 | 1 | a Mullol, J4 aut |
| 700 | 1 | a Munzel, U4 aut |
| 700 | 1 | a Price, D4 aut |
| 700 | 1 | a Scadding, G4 aut |
| 700 | 1 | a Virchow, JC4 aut |
| 700 | 1 | a Wahn, U4 aut |
| 700 | 1 | a Murray, R4 aut |
| 700 | 1 | a Bousquet, J4 aut |
| 710 | 2 | a Karolinska Institutet4 org |
| 773 | 0 | t International archives of allergy and immunologyd : S. Karger AGg 161:4, s. 369-377q 161:4<369-377x 1423-0097x 1018-2438 |
| 856 | 4 | u https://www.karger.com/Article/Pdf/351404 |
| 856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:127116960 |
| 856 | 4 8 | u https://doi.org/10.1159/000351404 |
Hitta via bibliotek
- International archives of allergy and immunology (Sök värdpublikationen i LIBRIS)
Till lärosätets databas
Hitta mer i SwePub
- Av författaren/redakt...
- Meltzer, E
- Ratner, P
- Bachert, C
- Carr, W
- Berger, W
- Canonica, GW
- visa fler...
- Hadley, J
- Lieberman, P
- Hampel, FC
- Mullol, J
- Munzel, U
- Price, D
- Scadding, G
- Virchow, JC
- Wahn, U
- Murray, R
- Bousquet, J
- visa färre...
- Artiklar i publikationen
- International ar ...
- Av lärosätet
- Karolinska Institutet
Sök utanför SwePub
- Sök vidare i:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - Nationella bibliotekssystem
- LIBRIS.kb.se
